Precocious Puberty Following Treatment in a Six-Year-Old Male with Congenital Adrenal Hyperplasia: Studies of Serum Luteinizing Hormone (LH), Serum Follicle-Stimulating Hormone (FSH) and Plasma Testosterone1

Authors:

Abstract
Subsequent to hydrocortisone therapy, serum LH, serum FSH and plasma testosterone concentrations were followed for 178 days in a 6.3-yr-old boy with congenital adrenal hyperplasia and a bone age of 13 yr. One day following the initiation of therapy, plasma testosterone concentration decreased from 346.8 ng/100 ml to 68.3 ng/100 ml. The lowest testosterone concentration (20.8 ng/100 ml) occurred on the 7th day following the initiation of therapy. An increase of serum LH (from 3.0 mIU/ml to 13.5 mIU/ml) and serum FSH (from 2.9 mIU/ml to 5.8 mIU/ml) concentrations into the adult male range (mean ± sd) LH 10.9 ± 4.0 mIU/ml and FSH 7.4 ± 1.9 mIU/ml) was observed on the 8th day. Mean (± sd) LH and FSH concentrations for the period extending from the 15th through the 124th day following the initiation of therapy were 12.7 ± 1.2 mIU/ml and 6.7 ± 0.8 mIU/ml, respectively. Mean (± sd) testosterone concentration for this period was 151.7 ± 76.4 ng/100 ml. By the 178th day following the initiation of therapy a significant increase in testicular size had occurred. This was associated with a serum LH concentration of 9.0 mIU/ml, a serum FSH concentration of 3.6 mIU/ml and a plasma testosterone concentration of 380.2 ng/100 ml. The data supports the hypothesis that the release of pituitary gonadotropins, subsequent to hydrocortisone therapy, is responsible for the normal pubertal changes observed in patients with congenital adrenal hyperplasia having bone ages of 12 yr or more.